Save up -80% on Filgrastim
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Neupogen
|$320.08||1 vial (1ml) 300mcg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Neupogen coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Filgrastim every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Filgrastim volume of distribution
The volume of distribution averaged 150 mL/kg in both normal subjects and cancer patients. The elimination half-life‚ in both normal subjects and cancer patients‚ was approximately 3.5 hours. Clearance rates of NEUPOGEN® were approximately 0.5 to 0.7 mL/minute/kg.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Filgrastim
Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.
Filgrastim mechanism of action
Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase
Dosage forms of Filgrastim
|Solution for injection/infusion||Subcutaneous or intravenous use||30 MU/0.5ml|
|Solution for injection/infusion||Subcutaneous or intravenous use||48 MU/0.5ml|
|Solution for injection or infusion||Subcutaneous or intravenous use||30 MIU|
G-CSF Granulocyte Colony Stimulating Factor
Humans and other mammals
Indication of Filgrastim
Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen – it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies.
Toxicity of Filgrastim
The effect of filgrastim (recombinant methionyl human granulocyte colony stimulating factor) on inflammatory cytokines and lymphocyte functions was studied in 24 healthy male volunteers (age range, 20-32 yr) who received either placebo or 75, 150, or 300 mug of subcutaneous filgrastim injection for 12 days in a double blind, placebo controlled, randomized parallel-group trial. Results showed that in all filgrastim treated groups, tumor necrosis factor alpha (TNF-alpha), interleukin 12 (IL-12), and interferon gamma (IFN-gamma) release by whole blood in response to endotoxin was reduced.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Filgrastim on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.